Pregnancy

Pregnancy is the state of carrying a developing fetus from conception through birth — roughly forty weeks in humans. It appears throughout this reference as a standing contraindication in substance safety listings, not because harm has been demonstrated for most compounds, but because the fetus shares circulation with the pregnant person and lacks the metabolic capacity to process many substances that adults tolerate.

The placenta filters some compounds and passes others freely. For most psychoactive substances, data on fetal exposure and developmental outcomes either come from retrospective studies of accidental exposure or have never been collected at all. The research gaps are large enough that caution appears in safety listings before evidence does.

How it is done

In harm reduction practice, pregnancy changes the risk calculation for every substance involved. The same compound that carries moderate risk for an adult may carry different risk for a fetus at a critical developmental window — the first trimester, when organ formation is ongoing, differs significantly from later stages for teratogenic risk.

The approach most used in clinical harm reduction for pregnant people is not abstinence enforcement but honest risk stratification: identifying which exposures carry the clearest evidence of harm, which represent data gaps, and which involve secondary risks — contamination, route of administration, withdrawal — that can be addressed more directly.

Where a substance is associated with physical dependence, the risk of discontinuation during pregnancy is weighed against ongoing exposure. Abrupt withdrawal from certain drug classes carries its own fetal risks, which is why managed withdrawal is the standard clinical approach rather than unassisted cessation.

What it cannot tell you

The most important limit of a pregnancy contraindication listing is that it does not distinguish between two very different situations: a substance with documented teratogenic effects and a substance for which reproductive or developmental toxicity data have simply never been published. Both appear as contraindications. The listing treats absence of safety evidence as a safety concern — which is not the same thing as evidence of harm.

A reader seeing the contraindication cannot determine from it alone whether the risk is theoretical or observed, whether it applies across all trimesters or only specific developmental windows, or whether it scales with how much or how often. These distinctions exist for a small number of well-studied compounds. For most substances indexed here, the data to make those distinctions have never been gathered.

The listing is also a prospective caution written before exposure occurs — it is not a risk assessment tool for exposures that have already happened. Someone seeking guidance after exposure during an unrecognized pregnancy is asking a different question than the one the listing was designed to answer.